Sonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution
March 27 2018 - 7:05AM
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care, today launched a new and
improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene
solution. Formulated from a patent-protected 100%
hypochlorous acid (HOCl) solution, the antimicrobial Acuicyn
removes encrustation and debris, helping to manage red, itchy and
inflamed eyes.
Now available in customized shatter-proof containers, Acuicyn is
a non-detergent-based proprietary solution of pure 100%
antimicrobial hypochlorous acid. It is now available via a
doctor’s prescription. Safe as saline, Acuicyn doesn’t sting
or burn making for pain-free application.
"I've recently switched over from using Avenova to Acuicyn
because Sonoma is the original U.S. medical-grade hypochlorous
acid company with a wide range of products that have helped
patients across many therapeutic indications around the globe,”
said Dr. Mary Boname OD, MS, FAAO, and president/owner at
Montgomery Eye Care. “I could not be happier with the
results. Not only are my patients satisfied with cleaner and
clearer eyes, Acuicyn’s cost is significantly less than the cost
of Avenova. I was pleased with Avenova, but I’m beyond
thrilled with Acuicyn!"
Acuicyn is available by prescription from U.S. optometrists and
ophthalmologists. For more information visit www.acuicyn.com.
About Chronic Eyelid and Eyelash
ConditionsMillions of people suffer from chronic eye
conditions caused by microorganisms that take up residence on
eyelids and eyelashes, resulting in myriad afflictions including
dry eye, MGD, blepharitis, demodex and eye allergies.
In particular, nearly 30 million Americans suffer from chronic
blepharitis, a fairly common eye condition that causes irritation
and inflammation of the eyelid margin where eyelashes join the
eyelid. While normally a mild condition, if not properly
treated, blepharitis can worsen to the point of negatively
impacting one’s vision. An equal opportunity affliction, it
impacts both children and adult, men and women, and people of all
ethnicities. One outcome of untreated blepharitis is the
onset of meibomian gland dysfunction or what is commonly called MGD
dry eye. Often accompanied by discomfort and loss of optimum
vision, MGD affects the quality of the tear film.
A similar affliction is dry eye syndrome, which burdens over 100
million people worldwide. As a result of natural aging and
modern living, risk of this disease increases 35% for each decade
after a person reaches the age of 40. As people grow older,
the production of oil in the body decreases, thus reducing tear
production while increasing evaporation of tears, resulting in
dryness of the eyes. This is further exasperated by increased
time in front of a computer screen.
Finally, the eyelash mite, also known as demodex folliculitis,
is a parasite found in the hair follicles of the face, particularly
in the eyelash area. When mites build up to a high level, it
can cause infection as well as loss of eyelashes. The
situation can worsen by not washing the face before bed. It
is estimated that 50% of Americans are afflicted with the eyelash
mites due to sleeping with their eye makeup on.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “believe,”
“achieve,” and “strive,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies,
as well as uncertainties relative to varying product formulations
and a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma®, Acuicyn™ and Microcyn® Technology are trademarks or
registered trademarks of Sonoma Pharmaceuticals, Inc. All other
trademarks and service marks are the property of their respective
owners.
Media and Investor
Contact:
Sonoma Pharmaceuticals,
Inc.Dan McFaddenVP of Public and Investor
Relations(425) 753-2105dmcfadden@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Sep 2023 to Sep 2024